Combined structure-based pharmacophore and 3D-QSAR studies on phenylalanine series compounds as TPH1 inhibitors

International Journal of Molecular Sciences

Volumn 13, Issue 5, 2012, Pages 5348-5363

  Ouyang, Liang ^a   He, Gu ^a   Huang, Wei ^b   Song, Xiangrong ^a   Wu, Fengbo ^a   Xiang, Mingli ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

3D QSAR; Inhibitors; Pharmacophore; Tryptophan hydroxylase

Indexed keywords

ENZYME INHIBITOR; LIGAND; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; TRYPTOPHAN HYDROXYLASE 1 INHIBITOR; UNCLASSIFIED DRUG; PHENYLALANINE; TPH1 PROTEIN, HUMAN;

ARTICLE; BINDING KINETICS; BIODIVERSITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DERIVATIZATION; DRUG STRUCTURE; ENZYME BINDING; IC 50; LIGAND BINDING; MOLECULAR MODEL; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RESIDUE ANALYSIS; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; VALIDATION PROCESS; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; HUMAN; METABOLISM;

DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PHENYLALANINE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN HYDROXYLASE;

EID: 84861566872     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13055348     Document Type: Article

References (27)

1. Martinez, A.; Knappskog, P.M.; Haavik, J. A structural approach into human tryptophan hydroxylase and its implications for the regulation of serotonin biosynthesis. Curr. Med. Chem. 2001, 8, 1077-1091.
2. Nichols, D.E.; Nichols, C.D. Serotonin receptors. Chem. Rev. 2008, 108, 1614-1641.
3. Zhang, X.D.; Beaulieu, J.M.; Sotnikova, T.D.; Gainetdinov, R.R.; Caron, M.G. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004, 305, doi:10.1126/science.1097540.
4. Matthes, S.; Mosienko, V.; Bashammakh, S.; Alenina, N.; Bader, M. Tryptophan hydroxylase as novel target for the treatment of depressive disorders. Pharmacology 2010, 85, 95-109.
5. Sikander, A.; Rana, S.V.; Prasad, K.K. Role of serotonin in gastrointestinal motility and irritable bowel syndrome. Clin. Chim. Acta 2009, 403, 47-55.
6. Liu, Q.Y.; Yang, Q.; Sun, W.M.; Vogel, P.; Heydorn, W.; Yu, X.Q.; Hu, Z.X.; Yu, W.S.; Jonas, B.; Pineda, R.; et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J. Pharmacol. Exp. Ther. 2008, 325, 47-55.
7. Ducy, P.; Karsenty, G. The two faces of serotonin in bone biology. J. Cell Biol. 2010, 191, 7-13.
8. Modder, U.I.; Achenbach, S.J.; Amin, S.; Riggs, B.L.; Melton, L.J.; Khosla, S. Relation of serum serotonin levels to bone density and structural parameters in women. J. Bone Miner. Res. 2010, 25, 415-422.
9. Rosen, C.J. Bone: Serotonin, leptin and the central control of bone remodeling. Nat. Rev Rheumatol. 2009, 5, 657-658.
10. Yadav, V.K.; Oury, F.; Suda, N.; Liu, Z.W.; Gao, X.B.; Confavreux, C.; Klemenhagen, K.C.; Tanaka, K.F.; Gingrich, J.A.; Guo, X.E.; et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138, 976-989.
11. Yadav, V.K.; Balaji, S.; Suresh, P.S.; Liu, X.S.; Lu, X.; Li, Z.S.; Guo, X.E.; Mann, J.J.; Balapure, A.K.; Gershon, M.D.; et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat. Med. 2010, 16, 308-312.
12. Shi, Z.C.; Devasagayaraj, A.; Gu, K.J.; Jin, H.; Marinelli, B.; Samala, L.; Scott, S.; Stouch, T.; Tunoori, A.; Wang, Y.; et al. Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J. Med. Chem. 2008, 51, 3684-3687.
13. Jin, H.H.; Cianchetta, G.; Devasagayaraj, A.; Gu, K.J.; Marinelli, B.; Samal, L.; Scott, S.; Stouch, T.; Tunoori, A.; Wang, Y.; et al. Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 5229-5232.
14. Jin, Y.; Qi, P.; Wang, Z.; Shen, Q.; Wang, J.; Zhang, W.; Song, H. 3D-QSAR study of combretastatin A-4 analogs based on molecular docking. Molecules 2011, 16, 6684-6700.
15. García, I.; Fall, Y.; Gómez, G. Using topological indices to predict anti-Alzheimer and anti-parasitic GSK-3 inhibitors by multi-target QSAR in silico screening. Molecules 2010, 15, 5408-5422.
16. Lu, S.; Liu, H.-C.; Chen, Y.-D.; Yuan, H.-L.; Sun, S.-L.; Gao, Y.-P.; Yang, P.; Zhang, L.; Lu, T. Combined pharmacophore modeling, docking, and 3D-QSAR studies of PLK1 inhibitors. Int. J. Mol. Sci. 2011, 12, 8713-8739.
17. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res. 2000, 28, 235-242.
18. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from proteinbound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 2005, 45, 160-169.
19. Discovery Studio, Version 1.7; Accelrys: San Diego, CA, USA, 2006.
20. SYBYL Molecular Modeling Software Packages, Version 6.9; Tripos Associates: St Louis, MO, USA, 2004.
21. Stahle, L.; Wold, S. Partial least squares analysis with cross-validation for the two-class problem: A Monte Carlo study. J. Chemom. 1987, 1, 185-196.
22. Cramer, R.D.; Bunce, J.D.; Patterson, D.E. Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant. Struct. Act. Relatsh.1988, 7, 18-25.
23. Marti-Renom, M.A.; Stuart, A.C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291-325.
24. He, G.; Qiu, M.H.; Li, R.; Ouyang, L.; Wu, F.B.; Song, X.R.; Cheng, L.; Xiang, M.L.; Yu, L.T. Multicomplex-based pharmacophore-guided 3D-QSAR studies of N-substituted 2'-(amino-aryl)benzothiazoles as Aurora-A inhibitors. Chem. Biol. Drug Des. doi:10.1111/j.1747-0285.2012.01366.x.
25. Lu, X.Y.; Chen, Y.D.; You, Q.D. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment. Chem. Biol. Drug Des. 2010, 75, 195-203.
26. Chaudhaery, S.S.; Roy, K.K.; Saxena, A.K. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors. J. Chem. Inf. Model. 2009, 49, 1590-1601.
27. Wellsow, J.; Machulla, H.J.; Kovar, K.A. 3D QSAR of serotonin transporter ligands: CoMFA and CoMSIA studies. Quant. Struct. Act. Relatsh. 2002, 21, 577-589.